Pharming Group (PHAR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.06
- Surprise
- -96.8%
- Revenue (period 2026-06-30)
- $90.2M
- Score today
- 5.4/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAR Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -96.8% surprise compares with a -1653.7% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Negative momentum
- Below 200-MA, MA slope -6.4%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.64
- Price target
- $11.27
- Stop
- $9.04
- Upside to target
- +16.9%
The stock trades at 72.6× trailing but 30.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 30 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
PHAR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $668.1M
- P/E (fwd)
- 30.7
- P/E (ttm)
- 72.6
- 52-week range
- $9.32–$21.34
- Off 52-week high
- 54.8%
- RSI (14)
- 30
- Volume vs avg
- 0.13×
- Score today
- 5.4/10